TY - JOUR
T1 - Thermo-responsive gold nanorod vesicles for combined NIR-II photothermal therapy and chemotherapy of solid tumors
AU - Xing, Wenqian
AU - Li, Ting
AU - Yang, Guangze
AU - Wu, Shuqin
AU - Pang, Bailu
AU - Xu, Yufang
AU - Qian, Xuhong
AU - Zhu, Weiping
N1 - Publisher Copyright:
© 2024 Acta Materialia Inc.
PY - 2025/1/15
Y1 - 2025/1/15
N2 - Photothermal therapy (PTT) is a promising treatment strategy for malignant tumors. Photothermal agents which can achieve efficient photothermal conversion in the NIR-II region plays crucial roles in this remedy. Here, we report one type of thermo-responsive gold nanorod vesicles USGRV-17-AAG for combined NIR-II photothermal therapy and chemotherapy of solid tumors. The nanovesicles are formed by self-assembly of gold nanorods modified with amphiphilic polymers (PEG45-b-PS450) and UCST-type polymers (P(AAm-co-AN)), and are loaded with the heat shock protein inhibitor 17-AAG. Upon 1064 nm laser irradiation, USGRV-17-AAG exhibits a high photothermal conversion efficiency (65.1 %) and thus can achieve temperature responsive release of tanespimycin (17-AAG), an inhibitor of HSP90. The combination of NIR-II photothermal therapy and chemotherapy can effectively eliminate tumor cells and inhibit the expression of HSP90. Intravenous injection of USGRV-17-AAG followed by 1064 nm laser irradiation revealed efficacious tumor ablation of tumor-bearing mice, with a tumor growth inhibition rate of 98.86 %. Therefore, USGRV-17-AAG can produce efficient anti-tumor effects and provides an alternative approach to the treatment of malignant tumors. Statement of significance: Photothermal conversion agents (PTAs) based on the near-infrared II (NIR-II) window are currently attracting significant attention for their promising development and diverse applications. In this study, thermosensitive drug-loaded nanovesicles, USGRV-17-AAG, were designed to enable NIR-II photothermal therapy in combination with chemotherapy. These nanovesicles were loaded with the heat shock protein 90 (HSP90) inhibitor 17-AAG, which effectively inhibits HSP90 expression and enhances the therapeutic efficacy of photothermal treatment. Additionally, USGRV-17-AAG exhibited efficient photothermal conversion (65.1 %) under 1064 nm laser irradiation and enabled temperature-responsive drug release through the action of surface-modified upper critical solution temperature (UCST) polymers. This nanocarrier, with enhanced NIR-II photothermal therapy, might offer a promising solution for anti-tumor treatment.
AB - Photothermal therapy (PTT) is a promising treatment strategy for malignant tumors. Photothermal agents which can achieve efficient photothermal conversion in the NIR-II region plays crucial roles in this remedy. Here, we report one type of thermo-responsive gold nanorod vesicles USGRV-17-AAG for combined NIR-II photothermal therapy and chemotherapy of solid tumors. The nanovesicles are formed by self-assembly of gold nanorods modified with amphiphilic polymers (PEG45-b-PS450) and UCST-type polymers (P(AAm-co-AN)), and are loaded with the heat shock protein inhibitor 17-AAG. Upon 1064 nm laser irradiation, USGRV-17-AAG exhibits a high photothermal conversion efficiency (65.1 %) and thus can achieve temperature responsive release of tanespimycin (17-AAG), an inhibitor of HSP90. The combination of NIR-II photothermal therapy and chemotherapy can effectively eliminate tumor cells and inhibit the expression of HSP90. Intravenous injection of USGRV-17-AAG followed by 1064 nm laser irradiation revealed efficacious tumor ablation of tumor-bearing mice, with a tumor growth inhibition rate of 98.86 %. Therefore, USGRV-17-AAG can produce efficient anti-tumor effects and provides an alternative approach to the treatment of malignant tumors. Statement of significance: Photothermal conversion agents (PTAs) based on the near-infrared II (NIR-II) window are currently attracting significant attention for their promising development and diverse applications. In this study, thermosensitive drug-loaded nanovesicles, USGRV-17-AAG, were designed to enable NIR-II photothermal therapy in combination with chemotherapy. These nanovesicles were loaded with the heat shock protein 90 (HSP90) inhibitor 17-AAG, which effectively inhibits HSP90 expression and enhances the therapeutic efficacy of photothermal treatment. Additionally, USGRV-17-AAG exhibited efficient photothermal conversion (65.1 %) under 1064 nm laser irradiation and enabled temperature-responsive drug release through the action of surface-modified upper critical solution temperature (UCST) polymers. This nanocarrier, with enhanced NIR-II photothermal therapy, might offer a promising solution for anti-tumor treatment.
KW - Controlled-release
KW - Gold nanorod vesicle
KW - Near-infrared-II
KW - Photothermal therapy
KW - Upper critical solution temperature
UR - https://www.scopus.com/pages/publications/85210540523
U2 - 10.1016/j.actbio.2024.11.035
DO - 10.1016/j.actbio.2024.11.035
M3 - 文章
C2 - 39603577
AN - SCOPUS:85210540523
SN - 1742-7061
VL - 192
SP - 353
EP - 365
JO - Acta Biomaterialia
JF - Acta Biomaterialia
ER -